Developing therapeutic monoclonal antibodies at pandemic pace.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32317764.
- Also identified by DOI 10.1038/s41587-020-0512-5 and PMC identifier 7173776.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Viral
- Drug Development
- Virus Diseases